KLOW Blend (BPC-157 + GHK-Cu + TB-500 + KPV)

BPC-157 Regulatory Notice: BPC-157 is currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review for potential designation as a bulk substance prohibited from compounding under FDCA Section 503A/503B. Regulatory status may evolve. This vial is a research reagent only.

WADA Notice - TB-500: TB-500 (Thymosin Beta-4 fragment) is classified under WADA S2.3 - Other Peptide Hormones, Growth Factors, and Related Substances and Mimetics, prohibited both in- and out-of-competition.

What is KLOW Blend?

KLOW Blend is a four-component peptide and peptide-metal complex research formulation co-formulating BPC-157 (Body Protection Compound 157, 10mg), GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper complex, 50mg), TB-500 (Thymosin Beta-4 fragment 17–23, 10mg), and KPV (Lys-Pro-Val, C-terminal alpha-MSH tripeptide, 10mg). Each component targets a mechanistically distinct molecular pathway: BPC-157 operates on the VEGFR2-Akt-eNOS angiogenic and FAK-paxillin cytoprotective axis; GHK-Cu engages Cu²⁺-mediated integrin signalling, MMP-2 modulation, and broad collagen synthesis gene regulation; TB-500 drives directional cell migration via G-actin sequestration and ILK pathway activation; KPV inhibits NF-κB nuclear translocation via PepT1-mediated cellular uptake and intracellular importin-α pathway modulation. The four non-overlapping mechanisms make KLOW Blend relevant to multi-pathway tissue repair, anti-inflammatory signalling, and ECM remodelling research in cell and animal model systems. It extends the three-component GLOW Blend with the addition of KPV as a fourth anti-inflammatory/mucosal repair pathway tool compound.

This compound is not approved by the U.S. FDA for human or veterinary use. Intended for laboratory and research purposes only. Not a dietary supplement or consumer product. BPC-157 is under FDA PCAC review. TB-500 is WADA S2.3 prohibited.

Chemical Properties

How Does KLOW Blend Work?

BPC-157 → VEGFR2 / eNOS / FAK-Paxillin Pathway: BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-AA pentadecapeptide derived from a gastric juice protein sequence. In preclinical cell models, it has been documented to upregulate VEGFR2 expression and activate the VEGFR2-Akt-eNOS signalling cascade, increasing nitric oxide (NO) production and endothelial cell proliferation. BPC-157 also activates focal adhesion kinase (FAK) and paxillin, facilitating directional migration of fibroblasts and repair cells in rodent organ injury models. Its resistance to gastric acid degradation and absence of a defined systemic receptor distinguish its pharmacological profile from classical growth factor research tools.

GHK-Cu → Cu²⁺ Integrin Signalling / MMP-2 Modulation / Collagen Synthesis: GHK (Glycyl-L-Histidyl-L-Lysine) coordinates Cu²⁺ with high affinity via the imidazole nitrogen of histidine and terminal amino groups of glycine. At 1–10 nM in fibroblast cultures, GHK-Cu has been documented to stimulate type I and III collagen synthesis, proteoglycans (dermatan sulfate, decorin), and MMP-2 gene expression while modulating TIMP balance (Pickart et al. 2015, PMID 26236730; Siméon et al. 2000, PMID 11045606) - enabling balanced ECM remodelling. Integrin-linked kinase (ILK) activation and downstream PI3K/Akt and MAPK pathway signalling are additionally documented in published fibroblast model data.

TB-500 → G-Actin Sequestration / ILK / Cell Migration: TB-500 (Ac-LKKTETQ, residues 17–23 of Thymosin Beta-4) sequesters G-actin monomers 1:1 via the WH2 actin-binding domain, maintaining the cytoplasmic pool available for rapid F-actin polymerization at the leading edge of migrating cells. This drives directional cell migration in fibroblasts, keratinocytes, and endothelial cells. ILK activation by TB-500/Tβ4 was documented in a murine cardiac repair model (Bock-Marquette et al. 2004, Nature, PMID 15558062). TB-500 is WADA S2.3 prohibited.

KPV → PepT1/NF-κB / Anti-Inflammatory Pathway: KPV (Lys-Pro-Val, CAS 67727-97-3) is the C-terminal tripeptide (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH), which retains the anti-inflammatory activity of the parent hormone while lacking significant melanocortin receptor pigmentation-driving agonism. In intestinal epithelial and immune cell models, KPV enters cells via the PepT1 (SLC15A1) di/tripeptide transporter and exerts a largely receptor-independent anti-inflammatory mechanism: at nanomolar concentrations, it inhibits NF-κB nuclear translocation by stabilising IκB-α and blocking p65/RelA nuclear import via the importin-α pathway (Dalmasso et al. 2008, Gastroenterology, PMID 18061177). Downstream effects documented in published preclinical data include suppression of TNF-α, IL-1β, and IL-6 production from activated macrophages and intestinal epithelial cells, without engaging the classical MC1R-mediated pigmentation pathway at research concentrations. Kannengiesser et al. (2008, IBD, PMID 18092346) documented KPV anti-inflammatory activity in DSS-colitis and CD45RBhi transfer colitis murine models.

What are the Potential Research Applications of KLOW Blend?

• Multi-pathway angiogenesis research: BPC-157 activates VEGFR2-Akt-eNOS; GHK-Cu upregulates VEGF and bFGF gene expression; TB-500 drives endothelial cell chemotaxis via actin dynamics. Three mechanistically non-overlapping angiogenic pathways in one formulation, enabling comparative multi-pathway vascular biology investigation in tube formation and scratch assay model systems
• Extracellular matrix and wound healing research: GHK-Cu modulates type I/III collagen synthesis, proteoglycan deposition, and MMP-2/TIMP balance; TB-500 promotes fibroblast migration; BPC-157 supports granulation tissue formation markers in preclinical models. Together, these three ECM-active components span collagen synthesis, cellular migration, and vascular ingrowth research axes
• NF-κB anti-inflammatory pathway investigation (KPV-specific): KPV's PepT1-mediated intracellular NF-κB inhibition provides a fourth mechanistic dimension not present in the GLOW Blend. Investigated in intestinal epithelial cell models (Dalmasso 2008, PMID 18061177), murine colitis models (Kannengiesser 2008, PMID 18092346), and macrophage TNF-α suppression assays
• Mucosal repair pathway research: The addition of KPV to the GLOW peptide platform introduces a mucosal and intestinal epithelial anti-inflammatory research axis - KPV's PepT1-mediated uptake and NF-κB pathway modulation in gut epithelial models provide a tool for investigating combined cytoprotective (BPC-157/VEGFR2) + anti-inflammatory (KPV/NF-κB) research designs in GI-relevant cell model systems

Note: These findings are based on early-stage preclinical research for individual component compounds. No controlled data exists for this specific four-component blend formulation. Results are not consistent across all models, and data remains limited.

What are the Potential Side Effects of KLOW Blend?

• No organ toxicity documented for any of the four components at research concentrations in published preclinical literature
• GHK-Cu contains Cu²⁺: at concentrations exceeding the physiological nanomolar range, excess copper may generate oxidative stress signals in cell model systems. Monitor copper homeostasis in extended cell model experiments
• KPV: no significant adverse signals documented in published murine colitis or intestinal epithelial model data at research concentrations. Oral bioavailability in plain (non-enteric-coated) formulations is low due to gastric peptidase degradation
• No controlled toxicological data exist for this specific four-component blend formulation. All signals are extrapolated from individual compound published preclinical data. Data remains limited and not consistent across all model systems

Risk & Handling

Handling Precautions

• Trained laboratory personnel only. PPE: nitrile gloves, laboratory coat, eye protection
• Reconstitute under aseptic conditions with sterile or bacteriostatic water. GHK-Cu copper content - use a copper-free buffer where copper chelation interference is a consideration in assay design

Exposure Risks

• Risk Tier: MODERATE - GHK-Cu contains Cu²⁺, which at supraphysiological concentrations may generate oxidative stress in cell models. TB-500 is WADA S2.3 prohibited - anti-doping compliance required for relevant research programmes. BPC-157 is under FDA PCAC review; regulatory position may evolve. No human safety data has been established for this specific four-component blend

Storage

• Store at −20°C, sealed, protected from light. Reconstitute with sterile or bacteriostatic water under aseptic conditions. Do not re-freeze reconstituted solution

FAQs

What does KPV add to the existing GLOW Blend (BPC-157 + GHK-Cu + TB-500)?

KPV introduces a fourth mechanistic axis not present in the GLOW Blend: PepT1-mediated intracellular NF-κB pathway inhibition via IκB-α stabilisation and p65/RelA nuclear import blockade. This adds a receptor-independent anti-inflammatory pathway to the existing VEGFR2/NO (BPC-157), Cu²⁺/MMP-2/collagen (GHK-Cu), and G-actin/ILK (TB-500) mechanisms, making KLOW Blend relevant to research designs requiring combined cytoprotective, ECM remodelling, and anti-inflammatory pathway investigation in a single formulation.

What is the BPC-157 regulatory status?

BPC-157 is under FDA Pharmacy Compounding Advisory Committee (PCAC) review for potential designation as a bulk substance prohibited from compounding under FDCA Section 503A/503B. It is not FDA-approved for any indication. This vial is a research reagent only. Monitor FDA announcements for updates.

What is TB-500's WADA classification?

TB-500 is classified under WADA S2.3 - Other Peptide Hormones, Growth Factors, and Related Substances and Mimetics and is prohibited both in- and out-of-competition. Research programmes involving subjects with anti-doping obligations must comply with applicable regulations.

How does KPV enter cells mechanistically?

KPV enters intestinal epithelial and immune cells primarily via PepT1 (SLC15A1), the proton-coupled di/tripeptide transporter expressed at high levels in intestinal epithelium. Inside the cell, KPV inhibits NF-κB nuclear translocation by stabilising IκB-α and blocking the p65/RelA subunit from binding importin-α - a receptor-independent intracellular mechanism documented at nanomolar concentrations in Dalmasso et al. 2008 (PMID 18061177).

Storage conditions?

Store at −20°C, sealed, light-protected. Reconstitute with sterile or bacteriostatic water under aseptic conditions. Do not re-freeze reconstituted solution.

References

• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. https://pubmed.ncbi.nlm.nih.gov/18061177/
• Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. https://pubmed.ncbi.nlm.nih.gov/18092346/

Disclaimer: KLOW Blend (BPC-157 + GHK-Cu + TB-500 + KPV) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co